Gene panel testing allows for the analysis of multiple genes beyond BRCA1 and BRCA2 that may also be associated with tumour development and/or treatment response, and their feasibility for guiding BC treatment is being considered in clinical trials [68, 70, 105]. The gene discussed is BRCA2; the disease is breast cancer.